Nissor Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 28-12-2024
- Paid Up Capital ₹ 0.50 M
as on 28-12-2024
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.00 M
as on 28-12-2024
- Revenue -41.22%
(FY 2021)
- Profit -4.58%
(FY 2021)
- Ebitda 8.36%
(FY 2021)
- Net Worth 51.98%
(FY 2021)
- Total Assets 0.16%
(FY 2021)
About Nissor Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹6.00 M.
Manish Satia, Jeet Champalal, Vansh Jain, and One other member serve as directors at the Company.
- CIN/LLPIN
U74900MH2015PLC264184
- Company No.
264184
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
08 May 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Nissor Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vansh Jain  | Director | 01-Mar-2019 | Current |
| Manish Satia | Director | 08-May-2015 | Current |
| Jeet Champalal | Director | 08-May-2015 | Current |
| Berkha Satia | Director | 10-Aug-2020 | Current |
Financial Performance of Nissor Pharmaceuticals.
Nissor Pharmaceuticals Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 41.22% decrease. The company also saw a slight decrease in profitability, with a 4.58% decrease in profit. The company's net worth Soared by an impressive increase of 51.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nissor Pharmaceuticals?
In 2021, Nissor Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nexus Lifecare Private LimitedActive 16 years 3 monthsManish Satia and Jeet Champalal are mutual person
Just Creativo Private LimitedActive 2 years 8 monthsManish Satia and Jeet Champalal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Sep 2018 | ₹6.00 M | Open |
How Many Employees Work at Nissor Pharmaceuticals?
Unlock and access historical data on people associated with Nissor Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nissor Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nissor Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
